Journal
JOURNAL OF BIOLOGICAL CHEMISTRY
Volume 285, Issue 48, Pages 37159-37169Publisher
AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
DOI: 10.1074/jbc.M110.152942
Keywords
-
Categories
Funding
- National Institutes of Health
- Chinese Ministry of Education [NCET-09-0315]
- NSFC [30600112, 30871255, 31071192]
- Shanghai key project [09JC1402300]
- Shanghai Leading Academic Discipline Project [B110]
Ask authors/readers for more resources
The TAZ transcription co-activator promotes cell proliferation and epithelial-mesenchymal transition. TAZ is inhibited by the Hippo tumor suppressor pathway, which promotes TAZ cytoplasmic localization by phosphorylation. We report here that TAZ protein stability is controlled by a phosphodegron recognized by the F-box protein beta-TrCP and ubiquitylated by the SCF/CRL1(beta-TrCPE) 3 ligase. The interaction between TAZ and beta-TrCP is regulated by the Hippo pathway. Phosphorylation of a phosphodegron in TAZ by LATS primes it for further phosphorylation by CK1 epsilon and subsequent binding by beta-TrCP. Therefore, the Hippo pathway negatively regulates TAZ function by both limiting its nuclear accumulation and promoting its degradation. The phosphodegron-mediated TAZ degradation plays an important role in negatively regulating TAZ biological functions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available